Stanton Sollenberger, DO
Neurology · Chambersburg, PANPI 1801900691
Payments from drug & device makers
Across 157 payments — averaging $12.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$249
- Novartis$234
- Supernus Pharmaceuticals, Inc.$227
- Avanir Pharmaceuticals, Inc.$206
- UCB, Inc.$167
- Sanofi$146
- plus $766 from 14 others
What the payments were for
- Speaking & faculty fees$362%
- Food & beverage$1,95898%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 21 | $249 |
| Novartis | 16 | $234 |
| Supernus Pharmaceuticals, Inc. | 20 | $227 |
| Avanir Pharmaceuticals, Inc. | 21 | $206 |
| UCB, Inc. | 10 | $167 |
| Sanofi | 12 | $146 |
| Biogen | 14 | $125 |
| Greenwich Biosciences, Inc. | 9 | $121 |
| EMD Serono, Inc. | 8 | $110 |
| AstraZeneca | 6 | $88 |
| Novo Nordisk | 3 | $71 |
| Genentech USA, Inc. | 4 | $57 |
| Lilly USA, LLC | 3 | $46 |
| Acorda Therapeutics, Inc | 3 | $36 |
| Scilex Pharmaceuticals Inc. | 2 | $26 |
| Amneal Pharmaceuticals LLC | 1 | $20 |
| Catalyst Pharmaceuticals, Inc. | 1 | $20 |
| AbbVie | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| CSL Behring | 1 | $13 |
How this compares
$1,994 in reported general payments places this provider in the 55th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 32 | $1,479 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 34 | $1,096 |
| Levetiracetam | 31 | $522 |
| Gabapentin | 39 | $401 |
| Donepezil Hcl | 63 | $257 |
| Divalproex Sodium ErDivalproex Sodium | 11 | $224 |
| Primidone | 20 | $108 |
| Metoprolol Succinate | 15 | $89 |
| ClopidogrelClopidogrel Bisulfate | 11 | $76 |
Paid to pharmacies, not to this prescriber.
Other neurology in Chambersburg
- David WeismanAbington$9.3M
- Amit Bar-OrPhiladelphia$7.7M
- Thomas LeistPhiladelphia$5.8M
- Jan DrappatzPittsburgh$4M
- Lauren ElmanPhiladelphia$3.3M
- David IrwinPhiladelphia$2.5M
- Paula ClemensPittsburgh$2.1M
- Anoopum GuptaPittsburgh$2M
- Daniel KremensPhiladelphia$1.9M
- Frances JensenPhiladelphia$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.